MDxHealth (NASDAQ: MDXH) furnishes 2025 interim report and confirms prelims

Rhea-AI Filing Summary

MDxHealth SA submitted a Form 6-K as a foreign private issuer to provide its 2025 Interim Report to investors. The interim report is attached as Exhibit 99.1 and contains the company’s detailed mid-year financial and operational information.

The company also formally confirms the accuracy of its previously released preliminary financial results that were furnished in a prior Form 6-K on August 5, 2025. The interim report is incorporated by reference into MDxHealth’s existing shelf registration statements on Form F-3, meaning those registration statements now include the latest interim information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/14/2025 - 05:20 PM Learn about SEC filing dates

FAQ

What does MDXH’s latest Form 6-K filing provide to investors?

The filing provides MDxHealth SA’s 2025 Interim Report as Exhibit 99.1, giving investors access to the company’s mid-year financial and operational information.

Did MDXH confirm its previously announced preliminary financial results?

Yes. MDxHealth SA confirms the accuracy of its preliminary financial results that were included in a press release furnished as Exhibit 99.1 to a prior Form 6-K dated August 5, 2025.

How is the 2025 Interim Report used in MDXH’s existing registration statements?

Exhibit 99.1, the 2025 Interim Report, is incorporated by reference into MDxHealth SA’s registration statements on Form F-3 (File Nos. 333-268885 and 333-280606), updating those documents with the latest interim information.

Is this MDXH Form 6-K considered filed or furnished under the Exchange Act?

The Form 6-K is being furnished, not deemed filed, for purposes of Section 18 of the Securities Exchange Act of 1934, limiting the associated liabilities unless specifically incorporated by reference elsewhere.

Who signed the MDXH Form 6-K and in what capacity?

The Form 6-K was signed on behalf of MDxHealth SA by Michael McGarrity, who serves as the company’s Chief Executive Officer.

Which prior MDXH SEC filing is referenced in this Form 6-K?

This Form 6-K references a prior Form 6-K filed on August 5, 2025, which contained a press release with preliminary financial results that are now confirmed as accurate.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-40996

MDXHEALTH SA

(Translation of registrant’s name into English)

CAP Business Center

Zone Industrielle des Hauts-Sarts

4040 Herstal, Belgium

+32 4 257 70 21

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

MDXHEALTH SA

This Report of Foreign Private Issuer on Form 6-K (the “Form 6-K”) consists of the 2025 Interim Report of MDxHealth SA (the “Company”), which is attached hereto as Exhibit 99.1. Additionally, the Company confirms the accuracy of the Company’s preliminary financial results included in the press release filed by the Company as Exhibit 99.1 to Form 6-K with the Securities and Exchange Commission on August 5, 2025.

This Form 6-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing. Exhibit 99.1 to this Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-268885 and File No. 333-280606), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.		Description of Exhibit
99.1		2025 Interim Report

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MDXHEALTH SA
Date: August 14, 2025	By:	/s/ Michael McGarrity
		Name:	Michael McGarrity
		Title:	Chief Executive Officer

2